The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial

Cancer

Volumn 122, Issue 22, 2016, Pages 3509-3518

  Drescher, Charles W ^a   Beatty, J David ^a,b   Resta, Robert ^b   Andersen, M Robyn ^a   Watabayashi, Kate ^a   Thorpe, Jason ^a   Hawley, Sarah ^a   Purkey, Hannah ^a   Chubak, Jessica ^c,d   Hanson, Nancy ^b   Buist, Diana S M ^c,d   Urban, Nicole ^a,d  

^a USA   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

genetic counseling; genetic testing; ovarian cancer; referral and consultation; risk assessment; surgical prevention

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; GERMLINE MUTATION; HUMAN; INFORMED CONSENT; INTERVENTION STUDY; MAMMOGRAPHY; OVARY CANCER; PEDIGREE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALPINGOOOPHORECTOMY;

EID: 84994322744     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30190     Document Type: Article

References (31)

1. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622.
2. Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst. 2005;97:1382–1384.
3. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–87.
4. National Comprehensive Cancer Network (NCCN). NCCN Guidelines v2.2016. Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed January 22, 2016.
5. Debniak T, Gromowski T, Scott RJ, et al. Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families [serial online]. Hered Cancer Clin Pract. 2015;13:3.
6. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–823.
7. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–1517.
8. Andersen MR, Thorpe J, Buist DS, et al. Cancer risk awareness and concern among women with a family history of breast or ovarian cancer. Behav Med. 2016;42:18–28.
9. Quillin JM, Krist AH, Gyure M, et al. Patient-reported hereditary breast and ovarian cancer in a primary care practice. J Community Genet. 2014;5:179–183.
10. Pujol P, Lyonnet DS, Frebourg T, et al. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. Breast Cancer Res Treat. 2013;141:135–144.
11. Sheppard VB, Graves KD, Christopher J, Hurtado-de-Mendoza A, Talley C, Williams KP. African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer. J Genet Couns. 2014;23:311–322.
12. Pal T, Cragun D, Lewis C, et al. A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers. 2013;17:367–375.
13. Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. JAMA Intern Med. 2013;173:96–103.
14. Petzel SV, Vogel RI, Bensend T, Leininger A, Argenta PA, Geller MA. Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic. J Genet Couns. 2013;22:662–673.
15. Eichmeyer JN, Burnham C, Sproat P, Tivis R, Beck TM. The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review. J Genet Couns. 2014;23:323–329.
16. Giovanni MA, Murray MF. The application of computer-based tools in obtaining the genetic family history. Curr Protoc Hum Genet. 2010;Chapter 9:Unit 9 21.
17. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. NCCN: Clinical Practice Guidelines in Oncology, version 1. 2013. Available at: NCCN.org. Accessed May 30, 2016.
18. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2480–2487.
19. Therneau T. A Package for Survival Analysis in S. R Package, version 2.37–7. 2014; Available at: http://CRAN.R-project.org/package=survival. Accessed May 30, 2016.
20. Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K. Adherence patterns to National Comprehensive Cancer Network guidelines for referral of women with breast cancer to genetics professionals [published online ahead of print April 5, 2014]. Am J Clin Oncol. doi: 10.1097/COC.0000000000000073.
21. Ropka ME, Wenzel J, Phillips EK, Siadaty M, Philbrick JT. Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev. 2006;15:840–855.
22. Halbert CH. Decisions and outcomes of genetic testing for inherited breast cancer risk. Ann Oncol. 2004;15(suppl 1):I35–I39.
23. Sweeny K, Ghane A, Legg AM, Huynh HP, Andrews SE. Predictors of genetic testing decisions: a systematic review and critique of the literature. J Genet Couns. 2014;23:263–288.
24. Kieran S, Loescher LJ, Lim KH. The role of financial factors in acceptance of clinical BRCA genetic testing. Genet Test. 2007;11:101–110.
25. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729–1736.
26. Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD. Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology. 2013;22:1336–1343.
27. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–490.
28. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:18032–18037.
29. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43:879–882.
30. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13:51–56.
31. Julian-Reynier C, Bouhnik AD, Mouret-Fourme E, et al. Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med. 2010;12:801–807.